Allergy Shots vs Drops: An Honest Evidence-Based Comparison

The most rigorous direct comparison — a 2015 network meta-analysis by Nelson et al. in the Journal of Allergy and Clinical Immunology: In Practice — found no statistically significant difference between SCIT and SLIT tablets for grass pollen, with a symptom score SMD of just 0.01. However, indirect comparisons disagree: Calderon et al. and Dretzke et al. (2013) found larger SCIT effect sizes in head-to-head indirect analyses, though with substantial heterogeneity. Where SCIT clearly has a stronger evidence base is for cat dander, mold, and tree pollen allergens — areas where single-allergen SLIT tablets are not available. Direct head-to-head RCTs are small (under 71 patients) and underpowered to detect the modest differences that may exist.

Sublingual immunotherapy drops have a substantially better safety record than allergy shots in terms of severe systemic reactions. AAAAI surveillance data from over 54 million injection visits (Epstein et al., 2019) documented 7 confirmed US fatalities over a decade, placing the fatality rate at approximately 1 per 2.5 million injections. SLIT has produced zero confirmed fatalities in worldwide clinical use, with approximately 11-30 published anaphylaxis case reports against an estimated 1 billion doses since 2000. This safety differential is the regulatory basis for FDA approval of at-home SLIT dosing after a supervised first dose, while SCIT requires clinic administration with a mandatory 30-minute post-injection observation period. The tradeoff is that SLIT tablets carry a boxed warning for severe reactions and require auto-injectable epinephrine to be prescribed.

Both modalities require at least 3 years of treatment to produce durable post-treatment benefit — the GRASS trial (Scadding et al., JAMA 2017) demonstrated that 2-year courses of either SCIT or SLIT failed to produce lasting benefit after stopping. After 3-year courses, both SCIT and SLIT-tablets show sustained benefit for at least 2-3 years post-treatment. Durham et al. (1999, NEJM) showed that 3-4 years of SCIT produced persistent clinical remission through at least 3 follow-up pollen seasons. Grass SLIT-tablet trials (Durham et al., JACI 2012) confirmed disease modification 2 years after stopping a 3-year course. Long-term data beyond 3 years post-treatment are stronger for SCIT (12-year pediatric follow-up, Eng et al. 2006) than for SLIT. Both appear to offer 5-10+ years of benefit after a complete 3-5 year course.

The adherence data show an apparent paradox: despite being less convenient, SCIT achieves higher 3-year completion rates (23%) than SLIT (7%) per the landmark Kiel et al. 2013 study of 6,486 Dutch patients published in the Journal of Allergy and Clinical Immunology. The likely explanation is that clinic-supervised SCIT injections enforce compliance — patients must physically show up and receive the injection from a provider. SLIT patients who are responsible for daily self-administration at home face the common barriers of forgetting, perceived lack of visible progress, and reduced accountability. The most cited reason SLIT patients quit is perceived lack of efficacy (25-55% of dropouts), while SCIT patients cite inconvenience as their primary reason (22-45%). Telehealth monitoring and regular check-ins have been shown to improve SLIT adherence significantly.

SCIT can treat virtually any IgE-mediated inhalant allergen — grasses, trees, weeds, dust mites, cat, dog, mold, and stinging insect venoms — using multi-allergen vials customized to a patient's sensitization profile. FDA-approved SLIT tablets are each limited to a single allergen: Grastek covers Timothy grass only, Ragwitek covers short ragweed only, Odactra covers dust mites only, and Oralair covers 5 grass species. This single-allergen limitation makes FDA tablets impractical for the approximately 60% of allergic patients who are sensitized to multiple allergen types. Compounded multi-allergen SLIT drops are an off-label alternative that can address multiple allergens, but they lack the phase-3 standardized evidence base of FDA-approved tablets, and their potency varies between compounding sources.

Commercial insurance covers in-office allergy shots (SCIT) without prior authorization at virtually all major payers. FDA-approved single-allergen SLIT tablets require prior authorization but are covered by most commercial insurers, with manufacturer copay assistance programs available. Medicare Part B covers SCIT at 80% but explicitly does NOT cover sublingual immunotherapy of any kind under National Coverage Determination 110.9. Compounded multi-allergen SLIT drops are generally not covered by any insurer because they are off-label, meaning patients typically pay the full cost out-of-pocket. The insurance coverage asymmetry — SCIT covered, SLIT not — is most pronounced for Medicare patients, and is an important practical consideration in the SCIT vs SLIT decision.

Real-world adherence is poor for both modalities, and most patients do not complete a full course. The landmark adherence study — Kiel et al. 2013, Journal of Allergy and Clinical Immunology, analyzing 6,486 Dutch patients from 1994-2009 — found only 18% of all patients reached 3 years of treatment. SCIT had a 3-year completion rate of 23%; SLIT had a 7% 3-year completion rate. The median treatment duration was 1.7 years for SCIT and 0.6 years for SLIT. By year 1, 62% of SLIT patients had already discontinued. These real-world rates contrast sharply with clinical trial completion rates, where 80-90% of participants complete study protocols under intensive monitoring. Treatment choice alone does not determine adherence — monitoring intensity, patient education, and structured follow-up have meaningful effects on completion rates for both modalities.